Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine liposome versus bupivacaine hydrochloride TFESI for thoracic zoster-associated pain
ChiCTR2400079664Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in herpes zoster (HZ) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Numeric Rating Scale pain score. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ChiCTR2400079664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079664.